Research funder · International
HORIZON EUROPE Health
- Grants since 2016
- 770
- Awarded, last 5 years (where amounts are published)
- €6.2B
- Funded works, last 5 years
- 2 122
- Funded works, all time
- 2 359
Grants
2026 · grant · HORIZON.2.1
Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins
2026 · grant · HORIZON.2.1
REcurrent urinary tract infection: Efficacy and safety of PHage theRapy and Microbiota transfEr
2026 · grant · HORIZON.2.1
Safety and efficacy of Dolutegravir and EFV400 for pregnant and breastfeeding women - a randomized non-inferiority clinical trial
2026 · grant · HORIZON.2.1
Strengthening secondary prevention of ischemic heart disease in rural Ukraine and Bulgaria: the SPIDR Consortium
2026 · grant · HORIZON.2.1
Preparedness, Research and Surveillance Network for infectious Diseases in Central Africa
2026 · grant · HORIZON.2.1
Advancing Clinical Care and Equity through Scalable Solutions in Alzheimer’s Disease diagnosis and treatment
2026 · grant · HORIZON.2.1
TUMOUR ACTIVATED IMMUNOTHERAPY FOR SOLID TUMOURS (TAIST)
2026 · grant · HORIZON.2.1
Strategic Training Hub for Infectious Disease Modelling in Sub Saharan Africa
2026 · grant · HORIZON.2.1
Decoding Early-Life UVA and Skincare Additive Interactions Driving Melanoma Risk and Progression in Young Adults
2026 · grant · HORIZON.2.1
European Pediatric Immunotherapy Trial with Combinatory ATMPs for DIPG
2026 · grant · HORIZON.2.1
COMMUNITY-BASED SCALE UP OF INTEGRATED COMMUNITY HEALTH WORKER-LED CARDIOVASCULAR RISK FACTOR MANAGEMENT - ComBaScale
2026 · grant · HORIZON.2.1
A Public Health Modelling and Data Science Fellowship Centre of Excellence in West and Central Africa
2026 · grant · HORIZON.2.1
A Phase 2a Randomised Clinical Trial to Identify the Optimal Dose of the Thermostable ID93+GLA-SE Tuberculosis Vaccine for Further Clinical Evaluation and Local Manufacture in Africa
2026 · grant · HORIZON.2.1
Training Initiative for Modeling Epidemic Response in Africa
2026 · grant · HORIZON.2.1
AI assisted innovative low-cost skin testing model to accelerate person-centered TB prevention services in Tanzania, Mozambique and Uganda.
2026 · grant · HORIZON.2.1
Clinical ResEArch Training fellowship with Industry involVEment
2026 · grant · HORIZON.2.1
EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB-SAHARAN AFRICA
2026 · grant · HORIZON.2.1
Multimodal data Integration and AI-based REsearch on environmental exposures in children and Young Adult cancers
2026 · grant · HORIZON.2.1
Recurrent TB Screening and Prevention Study
2026 · grant · HORIZON.2.1
Personalized-Phage Against E. Coli with IV Antibiotic to Knockout Stable Biofilms in Urinary Tract Infections
2026 · grant · HORIZON.2.1
Sustainable Training in Epidemiological Analysis and Modelling for Data-Driven Decision Making in Africa (STEAM-3D)
2026 · grant · HORIZON.2.1
The next leap in cancer care: combining multi-modality and spectral imaging, advanced therapies, robotics and AI to enable standardized, precise interventional oncology treatments for cancer patients
2026 · grant · HORIZON.2.1
PREParedness using Artificial Intelligence for Rapid VACcine design
2026 · grant · HORIZON.2.1
DIGITAL DASHBOARDS IN DIAGNOSTIC INNOVATIONS
2026 · grant · HORIZON.2.1
A NEW DAWN IN NEXT-GENERATION CAR-T MANUFACTURING
2026 · grant · HORIZON.2.1
A multicenter, double-blind Phase I/II trial evaluating safety and efficacy of a fixed phage cocktail vs. placebo + DAIR in treating S. aureus prosthetic joint infections.
2026 · grant · HORIZON.2.1
Phase I/II trial of an Oral ER-stress iNducer in relapsed/refractory neuroblastoma and paediatric solid tumours
2026 · grant · HORIZON.2.1
Actiphage-supported Clinical Tools for Knowledge-driven Innovations in Diagnostic Solutions for TB in young children
2026 · grant · HORIZON.2.1
DIGItalisation of the Conformity Assessment Process
2026 · grant · HORIZON.2.1
STRENGTHENING CAPACITY IN EPIDEMIC ANALYTICS AND MODELING IN CENTRAL AFRICA
2026 · grant · HORIZON.2.1
Phase IIa Double-Blind, Placebo- Controlled, Randomized, Efficacy and Safety Study of Subcutaneously Administered HER-096 in Patients with Early-Stage Parkinson’s Disease HERMOD
2026 · grant · HORIZON.2.1
EARLY NEUTRALIZING ANTIBODIES IN INFANTS LIVING WITH HIV TO ENHANCE THEIR LIFE
2026 · grant · HORIZON.2.1
FOSTERING OUTBREAK RESILIENCE THROUGH TRAINING, RESEARCH, EPIDEMIOLOGY, AND STATISTICAL SCIENCE TO STRENGTHEN THE SUB-SAHARAN AFRICA PUBLIC HEALTH WORKFORCE
2026 · grant · HORIZON.2.1
Improving patients' outcomes and fragmented specialized care through a connected and advanced Multidisciplinary-Cardio-Metabolic-Clinic
2026 · grant · HORIZON.2.1
A NOVEL MONOCLONAL ANTIBODY SOLUTION FOR LASSA FEVER - TRANSFORMING PROPHYLAXIS AND TREATMENT TO IMPROVE HEALTH SECURITY AND PANDEMIC RESILIENCE
2026 · grant · HORIZON.2.1
EU-HENIpavirus PROTECTion via inhaled antibody solution
2026 · grant · HORIZON.2.1
GENz-trials: Revolutionizing Clinical Trials to Optimize Assessment of Healthcare Innovations
2026 · grant · HORIZON.2.1
TOWARDS THE ELIMINATION OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN THROUGH IDENTIFICATION OF THEIR ENVIRONMENTAL CAUSES
2026 · grant · HORIZON.2.1
GeoAI toolbox for Epidemic Intelligence
2026 · grant · HORIZON.2.1